Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Core Insights - Genenta Science and ANEMOCYTE have announced a strategic collaboration focusing on off-the-shelf lentiviral vector (LVV) Plasmid DNA technology, expanding their existing partnership in plasmid DNA production [1][2][3] - The collaboration aims to enhance ANEMOCYTE's offerings by utilizing Genenta's established LVV Plasmid DNA technology, which is based on foundational research by Professor Luigi Naldini [2][3] - This partnership is expected to support the development of advanced therapy programs across the life sciences industry, ensuring clients have access to reliable and scalable solutions [3] Company Overview - Genenta Science is a clinical-stage immuno-oncology company developing a proprietary hematopoietic stem cell therapy for solid tumor cancers, with its lead product candidate being Temferon™ [5] - Temferon™ is designed to express immune-therapeutic payloads within the tumor microenvironment, potentially enhancing T cell responses and breaking immune tolerance [5] - ANEMOCYTE is a Biotech Manufacturing Organization based in Italy, specializing in the development and manufacturing of pDNA and mRNA, with over 25 years of expertise in innovative therapies [4]